Emerging Therapeutic Targets for Schizophrenia: A Focus on Muscarinic Acetylcholine Receptor Activation

As the understanding of schizophrenia advances, novel treatment strategies are reshaping the therapeutic landscape. This session will explore the growing evidence supporting muscarinic acetylcholine receptor activation as a promising target for schizophrenia management. Attendees will review the latest clinical data on emerging muscarinic receptor activators and their potential to address unmet needs beyond traditional dopamine-based therapies. Additionally, the session will provide practical insights into optimizing the placement of these agents within the treatment paradigm, with a focus on patient-centered care strategies. Join us for a forward-looking discussion on integrating these innovative approaches into clinical practice.

Supported by an independent educational grant from Bristol-Myers Squibb.